作者: sarah

祖龙娱乐发布2024年全年业绩

财务摘要︰- 2024年收益为人民币1,141.1百万元,较2023年同期增长25.6%。其中,综合游戏发行及运营业务收益同比增长45.9%至人民币1,035.0百万元,占总收益的90.7%。- 2024年毛利为人民币826.0百万元,较2023年同期增长27.0%,毛利率为72.4%,与去年同期保持基本一致。- 2024年研发开支同比减少8.6%至人民币532.1百万元,销售及营销开支增加至人民币565.0百万元,主要由于报告期内《龙族:卡塞尔之门》在中国大陆上线以及《以闪亮之名》持续进行运营推进所致。- 2024年经调整亏损净额较2023年同期收窄4.6%至人民币270.0百万元。营运摘要︰- 截至2024年全年业绩公告发布之日,集团在逾170个地区市场推出23款精品手游,支持14种语言的多个地区版本,已上线游戏的全球累计注册用户数超过2亿人,全球累计总流水超过人民币220亿元。  - 超自由时尚女性向手游《以闪亮之名》自上线以来,十余次以强劲之姿跻身中国大陆iOS游戏畅销榜前十名。伴随两周年庆活动序幕拉开,游戏不但于2025年3月4日跃居iOS游戏畅销榜第八,更是凭借高质量精准呈现的大屏效果,高居iPad畅销榜第二。截至2024年12月31日,《以闪亮之名》的全球累计注册用户数超过2,000万。  - 策略卡牌类游戏《龙族:卡塞尔之门》于2024年9月在中国大陆地区正式上线,上线首日即登顶iOS应用商店游戏免费榜并持续霸榜一周,且连续数日冲入游戏畅销榜前十名,成为祖龙娱乐又一款首月流水超过人民币1亿元的自主发行产品。  - 经典MMORPG手游《龙族幻想》以及回合制MMORPG手游《梦幻诛仙》持续实施多维度运营策略,有效实现了产品的长线平稳运营,保持了收益的持续稳定。- 为打造不同类型及多样化的游戏组合,集团预期于2025年至2027年期间在全球各地推出8款包括MMORPG、放置PRG、策略卡牌及其他类型的游戏产品,其中包括一款由虚幻引擎4打造的中国风修真题材放置RPG手游《踏风行》以及一款回合制MMORPG游戏项目代号:逍遥。香港, 2025年3月21日 - (亚太商讯 via SeaPRwire.com) - 祖龙娱乐有限公司("祖龙娱乐"或"公司",连同其附属公司,统称"集团",股份代号:9990.HK)公布其截至2024年12月31日止年度("报告期内")之经审核年度业绩。2024年,祖龙娱乐录得收益人民币1,141.1百万元,较截至2023年同期人民币908.5百万元增加25.6%,主要由于报告期内《龙族:卡塞尔之门》在中国大陆上线及《以闪亮之名》持续发力所致;其中,综合游戏发行及运营业务收益较截至2023年同期同比增长45.9%至人民币1,035.0百万元,占总收益的90.7%。2024年,集团毛利为人民币826.0百万元,较2023年同期同比增长27.0%,毛利率为72.4%,与去年同期保持基本一致。报告期内,集团研发开支同比减少8.6%至人民币532.1百万元,销售及营销开支增加至人民币565.0百万元,主要由于报告期内《龙族:卡塞尔之门》在中国大陆上线及《以闪亮之名》推广及广告开支增加所致。受上述因素综合影响,2024年集团经调整亏损净额较2023年同期收窄4.6%至人民币270.0百万元。《以闪亮之名》验证长线运营实力,新游上线助力产品赛道拓展以公司新一代女性制作策划团队为核心研发的超自由时尚女性向手游《以闪亮之名》,自上线以来十余次以强劲之姿跻身中国大陆iOS游戏畅销榜前十名,其2025年1月的单月利润更是创下该游戏的历史新高。伴随两周年庆活动序幕拉开,游戏不但于2025年3月4日跃居iOS游戏畅销榜第八,更是凭借高质量精准呈现的大屏效果,高居iPad畅销榜第二,当日流水攀升至一周年庆以来的峰值。2024年,游戏持续进行高质量的迭代更新,与中国邮政、上海海昌海洋公园、沙漠邮局等开展联动活动;更融入了蜀绣、泉州提线木偶戏、德化白瓷、京剧、柯尔克孜族刺绣、藏羌织绣等中国非物质文化遗产定制内容。此外,宠物系统凭借其单只可达三千万根毛发的极致毛流感和独特的渲染及染色工艺,叠加多样亲宠玩法,一经上线即获得玩家广泛关注。未来游戏还将解锁大地图以及模拟经营等更多新玩法,为玩家带来更丰富多元的游戏体验。《以闪亮之名》官方微博已累计获得超过1,700万个转评赞,TapTap平台评分持续高达8.9分。截至2024年12月31日,《以闪亮之名》的全球累计注册用户数超过2,000万。由虚幻引擎4打造的、根据《龙族》系列小说和动画改编开发的策略卡牌类游戏《龙族:卡塞尔之门》,于2024年9月12日在中国大陆地区正式上线。上线首日即登顶iOS应用商店游戏免费榜并持续霸榜一周,且连续数日冲入游戏畅销榜前十名,成为公司又一款首月流水超过人民币1亿元的自主发行产品。该游戏于2024年11月26日携手金坛刻纸推出"凭秋剪意"联动活动,将非遗瑰宝独特魅力融合游戏元素展现在玩家面前。值得关注的是,对于自上线以来已分别运营超过5年和8年的由虚幻引擎4驱动的MMORPG手游《龙族幻想》以及回合制MMORPG手游《梦幻诛仙》,凭借多维度的运营策略持续提升了用户体验。这些举措有效实现了产品的长线平稳运营,保持了收益持续稳定。多元游戏储备丰富产品矩阵,"研运一体"战略延长生命周期为打造不同类型及多样化的游戏组合,集团预期于2025年至2027年期间在全球各地推出8款包括MMORPG、放置RPG、策略卡牌及其他类型的游戏产品。其中,由虚幻引擎4打造的中国风修真题材放置RPG手游《踏风行》于2025年3月开启了新一轮付费测试,并预计将于2025年上半年在中国大陆地区正式上线,该游戏计划主要采用自主发行方式。另一款融合国风和卡通美学的回合制MMORPG游戏项目代号:逍遥,计划于2025年对外开展测试。此外,改编自《龙族》系列小說,并依托虚幻引擎5打造的开放世界MMORPG+游戏项目代号:Odin正在有序开发中。日后,随着产品类型由MMORPG、SLG、女性向、策略卡牌扩张至放置RPG等多品类和丰富多样的风格,及持续完善"研运一体"的有机模式,预期公司游戏的生命周期将进一步延长,这将对集团的收益作出更稳定及持续的贡献。技术创新驱动产品力提升,社会责任引领企业长期价值创新是祖龙娱乐持续发展的核心动力,技术是公司不断提升竞争力的重要支撑。作为游戏领域的先锋,祖龙娱乐率先将全球领先的虚幻引擎技术引入移动游戏开发,不断突破技术边界,探索未知的可能性。集团不断在大语言模型(Large Language Model,LLM)方面研究探索,并迅速开展在游戏产品内接入及本地化部署DeepSeek的工作。同时,公司的技术团队基于公司产品实际需求正在自主开发能够在游戏内嵌入高智能化NPC的模型架构,在控制成本的基础上更快实现智能化技术的升级与玩家体验的提升。此外,集团还在不断积极推进AIGC(Artificial Intelligence Generated Content)与UGC(User Generated Content)融合性创作的前沿尝试,力争让玩家能够更便捷地在游戏内进行创意表达。正是这种对技术的执着追求与创新实践,让祖龙娱乐屹立于行业的前沿。与此同时,作为行业中负责任且有温度的游戏公司,祖龙娱乐积极践行社会责任,笃定躬行社会公益,成功开展了"鸿鹄筑梦公益计划"、"龙行公益"等活动,在文化创新、产教融合等方面取得了可圈可点的表现。展望未来,作为中国领先的游戏研发与运营厂商,祖龙娱乐将继续走在游戏行业技术探索前沿,继续坚持精品化、多品类、研运一体、全球化的核心战略,持续开发各品类行业领先的精品游戏,在文娱领域持续探索和思考,对市场及用户的定位、玩家喜好、推广策略等挖掘更深刻的认识,脚踏实地,勇敢出发,为全球玩家创造卓越的在线娱乐体验。关于祖龙娱乐有限公司祖龙娱乐是中国手游行业的开拓者,专注于开发优质MMORPG、SLG、女性向、策略卡牌及其他类型的手游,开发优质手游的实力屡经验证,且注重核心游戏性体验品类的持续深耕。截至目前,祖龙娱乐在逾170个地区市场共推出23款精品手游,支持14种语言的多个地区版本,所提供的高质量的多元游戏组合拥有良好的市场声誉。 Copyright 2025 亚太商讯 via SeaPRwire.com.

22 3 月, 2025

超市及便利店连锁运营商 江苏宏信超市H股全球发售

发售摘要:- 香港公开发售将于2025年3月26日(星期三)中午十二时正(白表eIPO服务申请于上午十一时三十分)截止;- 发行价范围:2.50港元至3.00港元;- 每手1,000股;- 最大集资净额约1.177亿港元(于任何超额配股权获行使前);- 预期股份在2025年3月31日(星期一)于香港联交所主板开始买卖;- 绰耀资本有限公司为独家保荐人。香港, 2025年3月21日 - (亚太商讯 via SeaPRwire.com) - 江苏宏信超市连锁股份有限公司("公司",股份代号:2625)今日宣布全球发售及于香港联合交易所有限公司("香港联交所")主板上市之计划。江苏宏信超市连锁股份有限公司是一家粮油批发商,总部设在扬州,主要集中在苏中地区以"宏信龙"品牌经营超市及便利店零售业务。根据行业报告,按销售额计,公司于2023年在扬州超市运营商中排名第二,市场份额约为9.1%,及按销售额计,公司于2023年在江苏中部地区的超市运营商中排名第五,市场份额约为2.3%,及按2023年的销售额计,于江苏省超市营运商中排名第20位左右,市场份额约为0.4%。江苏宏信超市连锁股份有限公司计划发售的股份数目为53,562,000股(视乎超额配售权行使与否而定),其中,香港发售股份数目为5,357,000股(可予重新分配),国际发售股份数目为48,205,000股(可予重新分配及视乎超额配售权行使与否而定)。发售价范围2.50港元至3.00港元,每手买卖单位1,000股。是次香港公开发售于2025年3月21日(星期五)开始,并预期于2025年3月26日(星期三)中午十二时正(白表eIPO服务申请于上午十一时三十分)截止。公司H股预期将在2025年3月31日(星期一)于香港联交所主板开始买卖。假设超额配股权完全不获行使,倘发售价定为每股3.00港元(即发售价范围的上限),则全球发售的所得款项净额将增至约1.177亿港元。公司拟将全球发售的所得款项净额用作下列用途:- 约30.9%将用作开设新零售店铺,其中包括门店翻新,购买货价,购买冷藏设施、照明、空调、闭路电视监控系统及POS系统及用于安装消防安全系统。- 约41.2%将用作建立新配送中心,其中包括收购地块用于建设新配送中心,新配送中心的建设及购置货架、灯具及附属设施以及安装消防安全系统。- 约26.8%将用作建立新的餐食中央厨房,其中包括建设新中央厨房,采购机器及设备,购置及安装消防安全系统、通风系统、冷藏设施、公用事业、空调、闭路电视监控系统及配套设施及购买额外车辆,以向客户配送餐食。- 约1.1%将用于增强ERP系统及基础设施系统,以提高运营效率。公司已成功引入基石投资者Top Legend SPC,其同意认购H股为可按发售价(包括经纪佣金、证监会交易征费及联交所交易费)认购总额为500万美元的数目,禁售期为六个月。绰耀资本有限公司为独家保荐人。绰耀资本有限公司及民银证券有限公司为联席整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。建银国际(控股)有限公司为联席全球协调人、联席账簿管理人及联席牵头经办人。招银国际融资有限公司、盈立证券有限公司、星河证券有限公司、艾德证券期货有限公司、创升证券有限公司、长桥证券(香港)有限公司为其他联席账簿管理人及联席牵头经办人。 Copyright 2025 亚太商讯 via SeaPRwire.com.

22 3 月, 2025

Mitsubishi Shipbuilding Receives Additional Orders for Three Methanol-Fueled RORO Cargo Ships

TOKYO, Mar 21, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Shipbuilding Co., Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, has received additional orders for three methanol-fueled roll-on/roll-off (RORO) cargo ships(1) from Toyofuji Shipping Co., Ltd. (Aichi Prefecture), Miyazaki Sangyo Kaiun Co., Ltd. (Oita Prefecture), and Nichitoku Kisen Co., Ltd. (Hiroshima Prefecture). The three ships will be built at the Enoura Plant of MHI's Shimonoseki Shipyard & Machinery Works in Yamaguchi Prefecture, with scheduled completion and delivery in order from fiscal 2028.The ships will be approximately 168.0 meters in overall length and 30.2 meters in breadth, with 15,750 gross tonnage, and loading capacity for around 2,300 passenger vehicles.A windscreen at the bow and a vertical stem are used to reduce propulsion resistance, while fuel efficiency is improved by employing MHI's proprietary energy-saving system technology combining high-efficiency propellers and high-performance rudders with reduced resistance. The main engine is a high-performance dual-fuel engine that can use both methanol and A heavy fuel oil, expected to reduce CO2 emissions per transport unit by more than 20% compared to ships currently operated by heavy fuel oil and owned by Toyofuji Shipping, contributing to a reduced environmental impact. In the future, the use of green methanol(2) may lead to further reduction in CO2 emissions, including throughout the lifecycle of the fuel. Methanol-fueled RORO ships have already been entered service as ocean-going vessels around the world. This is MHI's second order for construction of coastal RORO vessels for service in Japan, following an order for two methanol-fueled RORO vessels placed with Mitsubishi Shipbuilding in June 2024.In addition, the significant increase in vehicle loading capacity and transport capacity per voyage compared to conventional vessels will provide greater leeway in the ship allocation schedule, securing more holiday and rest time for the crew, thereby contributing to working style reforms.Mitsubishi Shipbuilding, to address the growing needs from the modal shift in marine transport against the backdrop of CO2 reductions in land transportation, labor shortages, and working style reforms, will continue to work with its business partners to provide solutions for a range of societal issues by building ferries and RORO vessels with excellent fuel efficiency and environmental performance that contribute to stable navigation for customers.(1) Roll-on/roll-off (RORO) ships are cargo ships equipped with a vehicle ramp like a ferry, allowing cargo loaded on cargo beds such as trucks and trailers to be loaded and unloaded on their own, and transported.(2) Green methanol is a type of carbon-neutral fuel. It is a synthetic fuel made from sustainable biomass or captured CO2 and hydrogen produced from renewable energy.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2025 JCN Newswire via SeaPRwire.com.

22 3 月, 2025

Xforce HEV Model Premieres in Thailand

TOKYO, Mar 21, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) premiered a new hybrid electric vehicle (HEV) model of the Xforce compact SUV in Bangkok. Mitsubishi Motors (Thailand) Co., Ltd., the local production and sales company in Thailand, will manufacture the model at its Laem Chabang Plant. Bookings begin in Thailand today, followed by its first public appearance at the 46th Bangkok International Motor Show1.The Xforce is a five-passenger compact SUV that was developed based on the concept "Best-suited buddy for an exciting life," with a focus on the way compact SUVs are used in the ASEAN region. Following its introduction in Indonesia in November 2023, the Xforce was rolled out to other ASEAN countries such as Vietnam and the Philippines, Latin America, Africa, and the Middle East in 2024. As one of Mitsubishi Motors’ global strategic vehicles, it has been praised for its stylish yet robust, authentic SUV styling in a spacious and comfortable five-passenger cabin, all the while delivering a maneuverable, compact body size.The new Xforce HEV model is the latest addition to Mitsubishi Motors’ HEV lineup, offering Thai customers a new electrified option alongside the Xpander and Xpander Cross HEV models launched in Thailand in February 2024. Adopting an HEV system derived from the brand’s renowned plug-in hybrid EV (PHEV), it features higher fuel economy, eco-friendliness, and powerful acceleration. The Active Yaw Control (AYC) and other all-wheel control technologies complement the front-wheel drivetrain to enable safe, secure driving at will. Moreover, drivers can actively choose EV driving according to the situation, allowing them to drive quietly when needed without worrying about disturbing others.“Globally, HEVs are increasingly in demand as a key electrified option that does not require charging infrastructure,” said Takao Kato, president and chief executive officer, Mitsubishi Motors. “Given this trend, Mitsubishi Motors is proud to add the Xforce HEV model to our lineup in Thailand, which is one of our most crucial markets. Along with the Xpander HEV series, we are committed to driving electrification in the Thai market while also exploring future introductions to other countries.”For more information, visit https://www.mitsubishi-motors.com/en/newsroom/newsrelease/2025/20250320_1.html.  Copyright 2025 JCN Newswire via SeaPRwire.com.

22 3 月, 2025

中国生物制药(1177.HK)公布2024全年业绩

财务摘要 截至12月31日止年度 人民币2024年2023年变动    人民币亿元人民币亿元%收入288.7262.0+10.2%毛利率(%)81.5%81.0%+0.5 百分点销售及管理费用占收入比例(%)*42.1%42.2%-0.1百分点研发费用占收入比例(%)17.6%16.8%+0.8百分点本年度盈利63.651.0+24.9%归属于母公司持有者应占盈利**35.023.3+50.1%经调整非《香港财务报告准则》归母净利润***34.625.9+33.5%基于归属于母公司持有者之经调整非《香港财务报告准则》归母净利润计算之每股基本盈利(人民币分)18.9013.97+35.3%创新产品收入****120.698.9+21.9%占收入比例(%)41.8%37.8% 新产品收入*****100.980.5+25.4%占收入比例(%)35.0%30.7% 每股股息(港仙)7.05.0+40.0%-中期3.02.0+50.0%-末期4.03.0+33.3%*销售及分销成本加行政费用除以收入**归属于母公司持有者盈利同比显著增长主要受惠于本年度收入明显增长及录得出售附属公司收益***指撇除已终止经营业务、若干非现金项目以及联营公司及合营公司之盈利及亏损之影响后的归属于母公司持有者基本盈利****收入为销售额扣除销售折扣,创新产品包含创新药及生物类似药*****五年内上市的产品重点成果肿瘤创新药- 福可维(盐酸安罗替尼胶囊)目前已获批七个适应症。三项新适应症已向中国国家药品监督管理局药品审评中心(「CDE」)递交上市申请,另有三项新适应症的关键性临床试验已取得阳性结果,集团将于近期向CDE递交新增该等适应症的上市申请。此外,安罗替尼还有多项新适应症的临床研究正在III期,包含一线非鳞状非小细胞肺癌、一线结直肠癌等,预计将在未来几年逐步递交上市申请。- 亿立舒(艾贝格司亭)注射液通过三项全球多中心、随机、对照研究的关键性III期临床试验,与临床上常用的短效升白药和长效升白药进行了对比,证明了其疗效和安全性。艾贝格司亭于2023年成功纳入国家医保目录,并在2024年加速放量,成为集团收入增长的重要贡献品种。- 安方宁(格索雷塞片)是一款新型、高效的KRAS G12C抑制剂,于2024年11月获得NMPA的上市批准,用于治疗至少接受过一种系统性治疗的KRAS G12C突变型的晚期非小细胞肺癌。集团将深入挖掘格索雷塞的多适应症潜力,有望将其打造为肿瘤领域的又一款重磅产品。- 安倍斯(贝伐珠单抗注射液)、得利妥(利妥昔单抗注射液)、赛妥(注射用曲妥珠单抗)和帕乐坦(帕妥珠单抗注射液)分别于2023年2月、2023年5月、2023年7月和2024年12月获得NMPA的上市批准。该等生物类似药在2024年快速放量,加速了集团的收入增长。肝病创新药- 天晴甘美(异甘草酸镁注射液)是第四代甘草酸制剂,目前已获批3个适应症:慢性病毒性肝炎、急性药物性肝损伤和改善肝功能异常。异甘草酸镁是全球第一个99.9%的纯化体甘草酸,具有肝脏靶向性强、抗炎效果优、安全性高等优势。- 拉尼兰诺(泛PPAR激动剂)目前正在全球开展III期临床试验,用于治疗代谢功能障碍相关脂肪性肝炎(MASH)。2023年7月,拉尼兰诺被CDE纳入突破性治疗药物程序。拉尼兰诺是中国第一个进入临床III期的MASH药物,有望填补中国市场空白。呼吸系统创新药- 天晴速畅(吸入用布地奈德混悬液)是中国首款获批上市的布地奈德雾化剂型仿制药,打破了国内市场长期被原研垄断的局面,为国内气道慢性炎症患者带来了兼具有效性、安全性与经济性的高端制剂产品。该产品已被纳入集采范围,集团及时采取了一系列主动管理措施,包括管道下沉、拓展市场覆盖和集采外市场的二次开发,使其销售额在2024年实现了稳步增长。- 天韵(注射用多黏菌素E甲磺酸钠)于2021年首仿上市,是中国首款获批上市的注射用多黏菌素E甲磺酸钠,并于2023年成功纳入国家医保目录。目前,国内仅两家同通用名产品获批。集团通过积极的学术推广,不断拓展市场覆盖,天韵的销售额在2024年快速增长。外科/镇痛创新药- 泽普思(氟比洛芬凝胶贴膏)是中国首个获批上市的国产凝胶贴膏,连续多年蝉联外用镇痛市场份额第一位。氟比洛芬凝胶贴膏的销售额在过去几年保持增长态势,并在2024年实现了突破性增长。集团开发的第二代氟比洛芬贴剂预计将于2025年获批上市。其他- 2024年,第十批集采产品仅占本集团总收入的1%,集采风险基本出清。此外,集团自主研发的两款1类创新药,安柏尼(富马酸安奈克替尼胶囊)及安洛晴(枸橼酸依奉阿克胶囊),新增纳入医保目录,有望惠及更多患者。香港, 2025年3月21日- (亚太商讯 via SeaPRwire.com) -中国领先的创新研发驱动型医药集团-中国生物制药有限公司(「中国生物制药」或「公司」,连同附属公司统称「集团」)(股票编号:1177)公布截至2024年12月31日止12个月之经审核财务业绩。年内,集团录得收入约288.7亿元(人民币,下同),按年增长约10.2%。归属于母公司持有者应占盈利约35.0亿元,按年大幅增长约50.1%。基于归属于母公司持有者应占盈利计算之每股盈利约19.13分,按年显著增长约51.9%,该显著增长主要受惠于本年度收入明显增长及录得出售附属公司收益。扣除已终止经营业务之归属于母公司持有者应占盈利,应占联营公司及合营公司亏损(扣除相关税项及非控制权益),若干资产及负债之公允价值变动及一次性调整之减值,流动权益投资之公允价值亏损╱(利润)(扣除相关税项及非控制权益),股权激励费用(扣除相关税项及非控制权益),可转换债券债务部份之利息费用及汇兑(收益)╱亏损之影响后,经调整非《香港财务报告准则》归母净利润约人民币34.6亿元,按年增长约33.5%。集团流动资金保持充裕,资金储备总额约241.1亿元(计入流动资产之现金及银行结余约95.7亿元、计入非流动资产之银行存款约93.7亿元、理财管理产品总额约51.7亿元)。董事会建议派发末期股息每股4港仙(2023年:3港仙),连同已派发中期股息每股3港仙,全年合共派发股息每股7港仙(2023年:5港仙)。销售:强大销售体系持续发力,仿制药收入实现正增长集团以仿制为基石,全面推进创新转型,创新产品不断驱动销售增量,收入占比逐年提升。年内,创新产品收入达到120.6亿元,按年增长21.9%,占集团总收入比例达41.8%。年内,抗肿瘤用药之收入达约107.3亿元,占集团收入约37.2%。外科╱镇痛用药和肝病用药之收入分别约44.6亿元和34.4亿元,各占集团收入约15.4%和11.9%。此外,呼吸系统、心脑血管用药和其他等不同领域产品的销售持续贡献集团收入。其中,呼吸系统及心脑血管用药之收入分别占集团收入的约10.9%和7.5%。研发:全力以赴推动创新产品开发,积极申请各类专利集团继续专注抗肿瘤、肝病、呼吸系统和外科/镇痛四大治疗领域的新产品研发。截至报告期日,集团有在研创新药70个,其中抗肿瘤用药39个、肝病用药7个、呼吸系统用药13个、外科/镇痛用药6个,其他类用药5个。另外,集团还有65个在研仿制药産品。集团亦十分重视保护知识产权,鼓励成员企业积极申报各种专利,以提高核心竞争能力。年内,集团提交专利申请1,069项及获得专利发明授权349项。截至报告期日,集团累计有效专利及专利申请5,082项,累计获得专利发明授权1,958项。展望:聚焦核心业务和创新,继续推进「双路径」国际化发展战略中国医药市场凭借庞大的体量与递增的市场需求,在全球医药産业中占据关键地位。此外,医药産业作为关系国计民生的战略性産业,是国家政策引导和激励的重点扶持对象。同时,一系列的政策拓宽了创新药的定价空间,提升了药品可及性,创新药有望迎来更广阔的市场前景。集团秉承「专注创新、服务病患,成为全球领先的制药企业」的愿景,坚持全面创新,不断加大研发投入,自主研发能力持续增强,目前已构建完善的管线産品组合。同时,集团大力推进商务拓展和战略合作,力争成为全球制药与生物科技公司的最佳合作伙伴。目前,集团已进入创新成果收获期,预计到2027年,集团已上市创新産品数量将超过30个,创新産品收入占总收入比例将突破50%,这将强化集团在四大治疗领域的优势地位,为未来可持续发展注入强大动力。此外,集团以人工智能为核心驱动力,推动数字化战略升级,已完成DeepSeek、ChatGPT等AI模型的本地化部署,优化跨部门协作等关键业务,显著提升运营效率。同时,集团采用「双路径」国际化发展战略,加速创新发展。一方面,集团通过引进全球医药创新成果到中国,惠及中国病患;另一方面,集团拓展国际市场,瞄准全球尚未满足的临床需求。未来,集团将进一步聚焦核心业务和创新,持续提升四大治疗领域的研发效率和质量,并积极推进国际化布局,驱动业务高速增长和业绩稳步提升,为全球医药事业的发展贡献力量。有关中国生物制药有限公司(股票编号:1177)中国生物制药,连同其附属公司,是中国领先的创新研究和研发驱动型医药集团,业务覆盖医药研发平台、智慧化生産和强大销售体系全産业链。産品包括多种生物药和化学药,在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市,2013年入选MSCI全球标准指数之中国指数成分股;2018年入选恒生指数成分股;2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续五年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」,连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料,请浏览: www.sinobiopharm.com Copyright 2025 亚太商讯 via SeaPRwire.com.

21 3 月, 2025

ULVAC Developing Next-Generation Dilution Refrigerator for Quantum Computing by 2026

Chigasaki, Japan, Mar 21, 2025 - (JCN Newswire via SeaPRwire.com) - ULVAC, Inc. and ULVAC CRYOGENICS INC. announced that they are developing a next-generation dilution refrigerator for quantum computers with imput from IBM. This product will provide a cryogenic environment essential for the stable operation of quantum computers, and it also promotes technological development and collaboration with research institutions and enterprises. While cooling systems from overseas manufacturers currently dominate Japan’s market, ULVAC is establishing a domestic production framework to support the advancement of research and development in the country.Cryogenic Technology Supporting the Advancement of Quantum ComputingSuperconducting qubits in quantum computers require operation at temperatures near absolute zero, making advanced cooling technology essential. In response to this challenge, ULVAC is developing a new dilution refrigerator.Key FeaturesIn-House Manufacturing of Core Components: ULVAC independently develops and manufactures dilution refrigerators, pulse-tube cryocoolers, and vacuum components, ensuring a stable supply and long-term support.High Cooling Performance: Capable of maintaining cryogenic temperatures at the 10mK level, supporting the stable operation of qubits.Scalable Modular Design: Designed to accommodate future large-scale quantum computing environments.Market Background and ULVAC’s CommitmentIn the Japanese quantum computing research and industrial market, dilution refrigerators from overseas manufacturers are widely used. However, challenges such as prolonged delivery lead times and delays in maintenance support have become increasingly evident. To address this situation, ULVAC has established an independent domestic production system, ensuring a stable supply and rapid technical support to facilitate the continuous advancement of research institutions and enterprises.Engagement With IBM and Industry OutlookULVAC, with input from IBM, has been developing the next generation of dilution refrigeration systems that meet IBM’s specifications for their superconducting qubit-based quantum computers. The new cryogenics platform resulting from this development has the potential to advance the quantum computing industry, while also enhancing the global supply chain for cryogenic equipment.IBM is expanding its quantum hardware ecosystem to advance the commercialization of superconducting quantum computers, with cooling technology playing a critical role in this effort.“Our goal is to build increasingly complex quantum machines, which means we need partners, like ULVAC, to help develop important components that will allow us to scale both systems and the industry. We have a long history of partnering with ULVAC to build the complex tools necessary for our semiconductor business, and now we look forward to ULVAC becoming an important part of the quantum industry.”— Dr. Jay Gambetta, Vice President of Quantum, IBM Fellow.“ULVAC is committed to leveraging its expertise in vacuum and cryogenic technologies to deliver high-performance, reliable dilution refrigerators for the global quantum computing market. Moving forward, we will continue our collaboration with IBM to develop solutions that drive the advancement of quantum technology.”— Setsuo Iwashita, President and CEO, ULVAC, Inc.Future ProspectsThe quantum computing industry is expected to experience significant growth over the next decade. Leveraging its expertise in vacuum and cryogenic technologies, ULVAC aims to provide advanced cooling solutions that are accessible to more research institutions and enterprises. Currently, ULVAC is conducting evaluation tests in collaboration with IBM, including testing at IBM’s quantum data center in Poughkeepsie, New York this year, with industry deployment scheduled for early 2026.ULVAC remains committed to advancing cryogenic technologies to further the quantum industry with IBM and other industry partners.About ULVAC, Inc.Since its founding in 1952, ULVAC, Inc. has been a comprehensive vacuum equipment manufacturer, providing manufacturing equipment, components, analytical instruments, materials, and services based on its core technology—vacuum technology. Working with customers across a wide range of industries, including semiconductors, electronic components, displays, automotive, and pharmaceuticals, ULVAC is committed to driving cutting-edge innovation and creating new value. https://www.ulvac.co.jp/en/About ULVAC Cryogenics Inc.Since its founding in 1981, ULVAC Cryogenics Inc. has been engaged in the development, manufacturing, and sales of cryopumps and cryogenic equipment utilizing cryogenic and control technologies. The company was founded through the integration of the vacuum technology of Japan Vacuum Engineering Co., Ltd. (now ULVAC, Inc.) and the refrigeration technology of the U.S.-based Helix Technology Corporation (now Edwards Vacuum LLC). In Japan, ULVAC Cryogenics holds a 40% market share in cryopump sales. https://www.ulvac-cryo.com/?lang=enFor more information:ULVAC CRYOGENICS INC. Sales Planning DepartmentTEL +81-467-85-8884 / Mail cryokikaku@ml.ulvac.com  Copyright 2025 JCN Newswire via SeaPRwire.com.

21 3 月, 2025

Hitachi launches new brand design to advance era of sustainable global growth

TOKYO, Mar 20, 2025 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE:6501, "Hitachi"), today unveiled a bold new brand design that reflects the company's transformationto what it calls "True One Hitachi", with digital at its core. Officially launching on 1st April 2025, the new brand builds on the company’s legacy of engineering excellence and updates it to more clearly reflect Hitachi’s pioneering spirit andforward-looking focus, creating value as one Hitachi by further strengthening collaboration between its businesses.Ahead of the next Mid-term Management Plan, the brand refresh reflects Hitachi’s transformation over the years, bymodernizing the company’s visual identity for the first time in 25 years, with six key design assets, including an evolved logo so all Group companies adopt the same ‘Hitachi’ logo; refreshed colours; bespoke typeface; dynamic layouts; imagery; and graphic textures.Hitachi Sans, a new bespoke typeface created for Hitachi, ensures the new font acts as a unique signature ofHitachi’s brand identity. Hitachi has also added a new range of 3D tonal textures inspired by the brand’s origins and precision engineering expertise. They come in two styles - Red and Neutral - and will be used as a wide range of backdrops, both static and moving.The new brand design follows the announcement of incoming President and CEO, Toshiaki Tokunaga, and a new business structure that will accelerate the creation of Hitachi's unique value globally through leveraging strengths in IT, OT, and products.Toshiaki Tokunaga, who will become President and CEO of Hitachi, Ltd. from April 1, 2025, said: “This newbrand design demonstrates Hitachi Group's determination to unite and challenge itself for a new stage of growth, by leveraging the transformation it has already undergone.“To achieve sustainable growth and enhance corporate value for Hitachi, we believe it is essential to continuously transform our mindset and work practices by swiftly identifying and adapting to changes in the economy andsociety. The Hitachi Group, spread across the globe, will come together under a single brand design that symbolizes this transformation, to create unique value that only Hitachi can offer, while advancing social innovation initiatives.”About Hitachi, Ltd.Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the 3 business sectors of “Digital Systems & Services” - supporting our customers’ digital transformation; “Green Energy & Mobility” - contributing to a decarbonized society through energy and railway systems, and “Connective Industries” - connecting products through digital technology to providesolutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers.The company’s revenues as 3 sectors for fiscal year 2023 (ended March 31, 2024) totaled 8,564.3 billion yen, with 573 consolidated subsidiariesand approximately 270,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com. Copyright 2025 JCN Newswire via SeaPRwire.com.

21 3 月, 2025

巨星传奇将投资周杰伦2025「嘉年华」巡回演唱会三亚站

香港, 2025年3月20日 - (亚太商讯 via SeaPRwire.com) - 巨星传奇(06683)将投资周杰伦2025「嘉年华」巡回演唱会三亚站,继去年参与福州站、杭州站、长沙站、南京站及深圳站投资后,再度成为周杰伦《嘉年华》世界巡回演唱会的投资方之一。通过参与此类大型演唱会项目,公司旨在探索收入来源多元化的可能性,并致力于为股东及潜在投资者创造长期价值。展望未来,巨星传奇集团计划通过「IP+文旅」模式,将演唱会投资与 IP 运营结合,提升「周同学」IP 的国际影响力,并探索其旅游与经济潜力。公司拟通过创新策展,拓展 IP 多元化发展,例如开发更多联名商品、举办主题展览及推广线下互动活动,以进一步贴近粉丝与市场需求,增强「周同学」IP 的情感共鸣与文化价值。 Copyright 2025 亚太商讯 via SeaPRwire.com.

20 3 月, 2025

亨得利2024全年收入录得人民币10.44亿元

香港, 2025年3月20日 - (亚太商讯 via SeaPRwire.com) - 亨得利控股有限公司(「亨得利」或「公司」及其子公司「集团」,股票编号:3389)宣布截至2024年12月31日止12个月(「回顾年内」)之全年业绩。2024年,国际环境错综复杂,地缘政治冲突、区域性战乱及贸易保护主义愈演愈烈,世界经济增长动能依然偏弱。于中国而言,经济总量实现了新的突破,但风险隐患仍然较多。面对复杂的环境,本集团秉承「行稳致远」的原则,顺应市场调整业务,保生存、求发展,努力维护股东的利益。截至2024年12月31日止,本集团收入录得1,043,555,000元(人民币,下同;(2023年12月31日:1,421,454,000元),较去年同期下降了26.6%;高端消费配套业务等收入为688,104,000元(2023年12月31日:710,708,000元),较去年同期下降3.2%,大宗商品贸易收入为355,451,000元(2023年12月31日:710,746,000元),较去年同期下降50.0%。集团年度录得亏损约55,472,000元(2023年12月31日:溢利35,191,000元),股东应占亏损约为65,161,000元(2023年12月31日:溢利33,885,000元)。亏损的的主要原因是:销售及毛利下降,物业、厂房、设备的折旧费用上升及汇率波动导致营运单位产生外汇兑换亏损等。回顾年度内,中国经济压力承重,集团的高端消费配套业务受到了一定的影响。但集团采取多种措施应对复杂的经营环境,取得了较为明显的成效。年度内,高端消费配套业务的销售虽然有些许下降,但利润较去年同期仍有良好的提升。回顾年度内,集团的大宗商品国际贸易业务主要为铁矿石、动力煤及焦煤向中国内地的进口。受国际、国内经济环境的影响,铁矿需求走弱,矿砂及煤炭等产品的市场价格波动较大,致集团的国际大宗商品贸易额及利润较去年同期均有所下降。年度内,集团计划于墨西哥建设一个集清关、进口、运输、仓储于一体的大宗货物中转物流园区,致力于服务中国大型企业。2024年全球干散海运市场整体波动增长。集团紧抓市场上涨时机,大力拓展业务。年度内,集团成功开发了中国国家能源集团、澳洲兖矿、天元锰业集团、印度钢铁管理局有限公司、印度安塞乐米塔尔集团等一系列国内外知名大型矿山、电力和钢铁企业。在深耕传统运输航线外,首次开辟土耳其至中国铝矾土运输航线,幷签订了长期运输协议。本年度,集团海运业务收入与利润均取得了良好的成绩。当前,于全球来看,政治动荡不安趋势明显,经营环境依然复杂严峻。而中国内地经济运行除了外部环境变化带来的不利影响外,自身发展也面临一定的困难和挑战。但是,中国经济基础稳、韧性强、潜能大,长期向好的支撑条件和基本趋势没有变相信中国内地经济发展动能会持续增强,发展态势将持续向好。新的一年,本集团仍将坚持「行稳致远、持续经营」之原则,背靠中国内地「稳中求进、以进促稳」的经济发展环境,紧贴市场,谨慎而稳妥地继续国际贸易的进程,幷不断扩充与加强与国际贸易密切相关的国际海运业务,努力成长,以冀成为国际海运供应链中较强的一员,实现企业突破性的发展。集团亦仍将顺应市场需求,面向中国内地及国际双市场,不断提升商业空间一体化服务水平;调整高端名表配套产品的生产,同时展开有限多元化的业务进程,加强高端消费配套生产在珠宝、化妆品及手机等其他高端生活品领域的拓展,将商业空间美化服务扩充至生活空间美化服务领域等,继而成为高端消费配套生态链中不可或缺的一个独立环节。 Copyright 2025 亚太商讯 via SeaPRwire.com.

20 3 月, 2025

云顶新耀启动嘉善工厂伊曲莫德生产建设项目 加速本地化供应布局

香港, 2025年3月19日 - (亚太商讯 via SeaPRwire.com) - 今日,云顶新耀宣布正式启动伊曲莫德(VELSIPITY®)位于嘉善工厂的生产建设项目,以支持该药物的本地化生产,进一步满足中国及亚洲市场对溃疡性结肠炎(UC)治疗的需求。该项目总投资达7000万元,预计投产后年产能可达5000万片,供应范围涵盖中国大陆、中国香港、中国澳门、中国台湾、韩国及新加坡等市场。随着溃疡性结肠炎(UC)患者数量的持续增长,中国市场对创新疗法的需求日益迫切。预计到2030年,中国溃疡性结肠炎患者将增至约100万,对更高效、安全、便捷的治疗方案提出了更高要求。伊曲莫德是一款每日一次口服的一线先进疗法,适用于中重度活动性UC患者,具有快速起效、临床缓解、黏膜愈合及良好安全性等优势。该药物已在多个国家和地区获批,并在2024年12月获中国国家药品监督管理局(NMPA)正式受理新药上市申请(NDA),此外已在中国香港获得NDA受理,并纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录,正式惠及内地患者。嘉善工厂自2022年投入运营以来,已建立先进的生产设施和完善的质量保障体系,并符合全球良好生产规范(GMP)标准认证。在政府的大力支持下,该基地不仅承担伊曲莫德及其他创新药的生产任务,还将作为云顶新耀mRNA技术平台本地化的战略支点,支持mRNA肿瘤及自免治疗药物的从研发到商业化全流程,进一步强化公司在创新药物生产领域的核心竞争力。目前,云顶新耀已成功本地化经过临床验证的自主研发mRNA技术平台,并在个性化肿瘤治疗性疫苗(PCV)、肿瘤相关抗原疫苗(TAA)、免疫调节肿瘤疫苗和自体生成CAR-T四大方向实现全面布局。在近期投资者交流会上,公司披露了最新的mRNA管线进展,公司自主研发的首款mRNA个性化肿瘤治疗性疫苗EVM16已在北京大学肿瘤医院完成首例患者给药,EVM14及自体生成CAR-T项目亦取得重要的临床前研究数据,进一步验证了mRNA技术平台的潜力。云顶新耀的mRNA技术平台依托深度学习的自研"妙算"系统(EVER-NEO-1)新抗原预测算法,能够精准筛选高免疫原性肽段,优化mRNA疫苗抗原设计,提高免疫应答效果。经过四年多的持续优化,公司已成功迭代至第三代mRNA序列设计算法系统,其新抗原预测能力表现出行业领先水平,进一步夯实了云顶新耀在mRNA创新药物研发领域的技术壁垒。嘉善工厂生产建设项目的启动,不仅彰显了云顶新耀对伊曲莫德市场前景的信心,也为公司其他创新药的本地化供应奠定了基础。通过全面提升生产和质量管理体系,云顶新耀正在实现从研发、生产到商业化的全价值链条整合,进一步巩固其成为亚洲领先的全球综合性生物制药公司。 Copyright 2025 亚太商讯 via SeaPRwire.com.

20 3 月, 2025

MASH疾病领域的大市场、大需求

香港, 2025年3月19日 - (亚太商讯 via SeaPRwire.com) - 代谢相关脂肪性肝炎(MASH)已成为全球医药行业正在挖掘的潜力"富矿" - 2030年MASH市场规模将突破322亿美元,患者人数超4.8亿,至今FDA仅批准了一款药物。MASH作为一种与代谢紊乱相关的肝脏疾病,表现为肝脏中脂肪异常堆积,并伴随炎症和肝脏纤维化,可进展为肝硬化和肝细胞癌,是全球肝移植的主要病因,更显著增加了心血管疾病的风险。随着生活方式的改变,这个潜在的"健康杀手"早已随肥胖、糖尿病等代谢问题一起悄然而快速地蔓延。这使得近年来代谢性肝病市场规模持续迅猛增长。近日,中国创新药物医学大会暨2025CMAC年会在苏州召开,会议以"凝医学新知、聚创新之力"为主题,汇聚行业精英和权威学者,共同探讨创新药物医学的发展趋势与挑战。MASH作为近年来越来越受到大众、医学界和产业界关注的热点疾病,大会专为此设主题分论坛:"MASH 临床药物研发与创新技术:全球视野下的实践与应用"。作为国内代谢疾病创新药企代表,君圣泰医药创始人刘利平博士应邀出席,并做了《MASH临床研究与市场机遇》的专题报告,同与会各专家分享交流。MASH赛场迎来关键赛点,多靶点、联合机制成为趋势2024年3月,Madrigal公司的Resmetirom获批上市,成为FDA批准的首款MASH治疗药物,这一突破标志着MASH药物研发迎来关键破局点看、迈入新阶段。另一方面,MASH庞大的全球患者规模以及大众对于代谢和健康的综合改善诉求,使得Resmetirom远未能解决庞大的治疗需求与有限的治疗手段之间的巨大矛盾。市场需要更能有效改善肝脏组织学,且为患者带来综合获益的药物。目前,多款MASH在研药物已进入临床后期,然而单一机制药物往往难以兼顾MASH治疗的多重需求:既改善肝脏脂肪变性,又抑制肝脏炎症及纤维化,同时为MASH关联的代谢共病(如,糖尿病、肥胖、心血管疾病等)带来治疗获益。因此,具备多靶点、多功能作用的创新疗法正成为新的研发趋势。君圣泰医药正是这一趋势的领航者。其核心产品熊去氧胆小檗碱(HTD1801)是一款全球独创的双机制小分子药物,兼具激活AMPK与抑制NLRP3炎症小体生成。代谢调节与抗炎两种机制联合互补,有利于从根本上恢复代谢健康,在改善肝脏代谢、抑制炎症及纤维化等方面展现出独特的临床优势。这种双管齐下的治疗策略,为MASH患者提供了更全面的优选治疗方案,在临床中展现出差异化优势。HTD1801双机制"组合拳"出击,在国际赛场获认可HTD1801治疗MASH的有效性已在临床2a期研究被验证,在MASH合并2型糖尿病(T2DM)患者中,HTD1801能显著降低肝脏脂肪含量,并在改善肝损伤及血糖控制等方面表现优越。该临床2a期研究结果已发表在全球顶级期刊Nature Communications上,结果显示:- 经HTD1801治疗后,MASH合并T2DM患者的肝脏脂肪含量显著降低,降低幅度约为安慰剂组的3倍,同时多个肝损伤相关指标得到改善,提示HTD1801具有为肝脏带来组织学上显著获益的潜力。- 经HTD1801治疗后,可改善多个心血管代谢风险因素,对血糖、体重、LDL-C及甘油三酯等指标均有显著改善,为患者带来多维获益。HTD1801多次亮相于国际顶级肝病大会,在2024年举办的欧洲肝脏研究学会年会(EASL)和美国肝病研究协会肝病年会(AASLD)上,展示了多项该2a期临床试验的事后分析,数据显示:- HTD1801与"顶流药物"GLP-1受体激动剂联用,预计可为MASH合并T2DM的患者带来降糖、降脂以及减轻体重的进一步获益。- 改善致病根本:胰岛素抵抗是MASH发生的"种子",而在胰岛素抵抗更严重的患者中,HTD1801带来更大的治疗获益。- HTD1801具备高安全性,可成为慢性病(如MASH和T2DM)长期管理的理想选择。此外,与FDA获批药物Resmetirom相比,HTD1801在血糖控制和减重方面表现出更优的治疗效果。目前,HTD1801的IIb期临床试验正在顺利推进,已在2024年3月完成在中美两地的患者入组,预计将在2025年公布顶线数据。随着MASH成为代谢病领域的新焦点,全球创新药企正加速布局,以多靶点、多功能创新疗法为代表的新一代药物正在逐步推进临床。HTD1801凭借其兼具能量稳态调节与抗炎作用的独特机制和差异化临床优势,展现出广阔的治疗潜力。 Copyright 2025 亚太商讯 via SeaPRwire.com.

20 3 月, 2025

康哲药业(00867)发布2024年度业绩:聚焦创新与专科突破 重塑增长动能

深圳, 2025年3月19日 - (亚太商讯 via SeaPRwire.com) - 3月17日,康哲药业发布2024年度业绩,公司全年实现营业收入人民币74.69亿元,同比下降6.8%;若全按药品销售收入计算,营业额为人民币86.22亿元,同比下降9.0%;实现净利润人民币16.13亿元,剔除相关资产减值损失计提后的正常化净利润为人民币17.14亿元。公告显示,公司业绩下滑主要受国采执行影响,三款未中标原研药2024年收入同比下降28.8%至人民币26.91亿元(全按药品销售收入计算)。然而,对于公司而言,2024年既是挑战中的"重塑之年",更是光芒初现的"突破之年"。公司整体业绩虽正经历短期阵痛,但独家药、创新药发展却不乏亮点,潜力已初步显现。公司2024年全按药品销售收入计算的独家产品及创新产品营收达人民币45.51亿元,同比增长4.1%,占总营业额的比重达到52.8%。本年度公司累计5款创新药进入商业化,但均处于早期市场导入阶段,未来随着已上市创新药逐步铺开大规模临床应用、快速放量,以及储备优质创新管线源源不断获批上市,公司将进入由独家药、创新药驱动的高质量、可持续发展新周期。公告显示,2024年康哲药业递交了重磅白癜风治疗创新药芦可替尼乳膏等2款新药的中国NDA,新增3项创新合作、3款医美产品合作。截至2024年底,公司已储备的短、中、长期创新管线总计近40项。此外,公司东南亚业务正蓄势待发,本年度已推动超过 5 款创新药递交上市注册申请,且联营公司的新加坡工厂前序准备工作基本完成,即将全面开展药品CDMO、销售推广业务,培育第二增长曲线。产品力为核心 夯实创新增长引擎作为深耕医药市场三十余年、已推动多款在售药品取得领先市场地位的药品商业化龙头,康哲药业在布局创新药时也秉持着敏锐的市场洞察,以一线需求指导立项,优选全球FIC、BIC创新药,其需符合"三好品种"筛选标准:具有学术差异化优势、较大市场潜力与良好竞争格局、及综合投资回报率高。从公司已上市的创新药来看,5款产品或是较市场既有品种有明显差异化优势,或在细分领域填补了市场空白,因而能为患者提供有价值的创新治疗方案。举例来说,用于慢性肾脏病(CKD)患者降磷的维福瑞(蔗糖羟基氧化铁咀嚼片)是经中国NMPA批准上市的首个铁基-非钙磷结合剂,并填补了国内12-18岁CKD4-5期或接受透析治疗的CKD患儿的降磷治疗用药空白,根据全球多项临床研究、真实世界研究资料(如发表在学术期刊International Urology and Nephrology、Clinical Nephrology的文献)及产品中国说明书,与其他磷结合剂相比,服用维福瑞的患者平均日服药片数减少了约50%,血磷达标率可提高95%;而益路取(替瑞奇珠单抗注射液)是一款靶向 IL-23p19亚基、治疗中重度斑块状银屑病的创新生物制剂,维持期只需每3个月给药一次,凭借其优异的长期疗效、便捷的用药周期和较好的安全性,有助于提升患者依从性。公司以优异的产品力为核心,并借助多年积累的丰富学术资源、推广经验,将有望实现已上市产品市场渗透力和品牌影响力的快速提升。公司目前处于NDA审评阶段、有望于2025年上市的2款创新药,芦可替尼乳膏、德昔度司他片,均被认为具备高市场潜力。根据公告,芦可替尼乳膏是截至目前美国FDA以及欧洲EMA批准的首个也是唯一一个局部 JAK 抑制剂白癜风复色产品,若成功上市,将为国内超千万深受困扰、无对症药物可用的白癜风患者带来治疗曙光。德昔度司他片用于治疗非透析成人CKD患者的贫血,并采用口服给药方式,中国III期临床试验结果显示,其在有效性、安全性和耐受性方面均表现良好。数据显示,我国CKD患者约有1.32亿,贫血是其常见并发症之一,产品上市后有望进一步满足CKD患者的贫血治疗需求。此外,公司已储备的、将于未来2至4年内获批上市的创新管线中,也有多款市场关注度高、业内评估有望成为FIC与BIC的大品种,如用于卒中治疗的注射用Y-3 、高选择性小分子口服JAK1抑制剂povorcitinib(非节段型白癜风、化脓性汗腺炎)、URAT1抑制剂ABP - 671(痛风)、抗IL-4Rα人源化单抗注射液 MG-K10(特应性皮炎)、口服改良型新药ZUNVEYL(阿尔茨海默病)等,可有力支撑公司未来业绩的持续增长。值得关注的是,康哲药业始终坚持"合作开发+自主研发"并举的高效创新路径,重视研发资源投入效益最大化。2018年至2024年,公司累计研发开支为人民币43.5亿元,占同期全按药品销售收入比重为7.6%,其中费用化研发投入为人民币8.8亿元,占同期全按药品销售收入的1.5%。公司通过较为审慎的研发投入,实现多个优质创新产品的成功立项、临床开发与上市,创新投入产出效率极高。此外,2024年底公司银行结余及现金达人民币37.07亿元,为持续加码创新、深耕前沿领域提供了充足保障。专科聚焦强化商业化体系 赋能产品价值释放强产品力与高效商业化能力协同发力,是康哲药业保持竞争优势的关键。康哲药业持续优化专科业务聚焦的商业化体系,形成以心脑血管/消化、皮肤/医美、眼科为核心的专科深耕格局,已积累丰富的专业推广网络和学术平台,为创新产品的成功商业化保驾护航。2021年起独立运营的皮肤医美业务公司"康哲美丽",正成长为中国领先、专业聚焦皮肤健康的创新型医药企业。康哲美丽已构建起以皮肤处方药为核心,并涵盖皮肤学级护肤品、轻医美产品的全产品矩阵。截至2024年底,其皮肤处方产品组合已全面覆盖白癜风、银屑病、AD、静脉炎、静脉曲张及化脓性汗腺炎等多种皮肤疾病;皮肤学级护肤品方面,专研敏感肌养护的"禾零舒缓产品系列"进一步完善,并新增"喜辽妥®壬二酸产品系列",为痘肌修护提供全套解决方案;轻医美业务方面,童颜针中国注册申请已获受理,并引入少女针、微晶瓷、脱细胞基质植入剂三款处于中国注册性临床阶段的再生类产品,进一步完善轻医美产品线。康哲美丽以多元的皮肤健康与美学产品矩阵,为不同皮肤健康需求人群提供全面、综合解决方案。同一时期开始独立运营的眼科业务公司"康哲维盛"则专注于眼科处方药、医疗器械及耗材的开发与商业化。在中国,眼病患者数量庞大,且人口增长和老龄化导致眼科疾病负担显著上升。康哲维盛借助眼科领域专业产品组合、广泛的网络及渠道资源等,持续巩固产品品牌力及学术地位,致力于成为中国领先的眼科药械公司。截至2024年底,康哲药业拥有约4,700名市场及推广人员,推广网络覆盖全国超5万家医院及医疗机构、约30万家零售药店。依托覆盖广泛的推广网络、执行高效的推广团队,公司围绕已上市创新药和核心独家产品,动态优化市场策略、推动真实世界研究及上市后临床研究,持续积累学术证据,强化产品学术影响力并加速转化为市场价值。同时,本年度内公司强化院外市场覆盖深度与广度,并通过线上线下融合、多渠道协同,实现院外引流与患者获益的双向提升。以东南亚为起点 培育海外业务第二增长曲线在深耕中国市场的同时,康哲药业加快国际化步伐,以东南亚为起点,借助当地对高性价比医药产品需求迅速增长这一有利契机,积极培育海外业务增长引擎,为公司长期、可持续增长注入新的动力。2024年,东南亚业务公司"康联达健康"结合区域特征与疾病谱特点,精准规划产品组合与商业化路径,多款产品的上市注册取得阶段性进展,为后续市场推广与销售落地奠定基础。本年度内,康联达健康获得创新产品povorcitinib(选择性小分子口服JAK1抑制剂,有望为相关自身免疫性和炎症性皮肤病患者带来新的治疗选择)东南亚十一国的独家许可权利。同时,康联达健康亦积极推进芦可替尼乳膏、益路取、莱芙兰、维图可、维福瑞等多款创新产品在东南亚及/或港澳台市场的上市注册工作。其中,芦可替尼乳膏已于澳门、香港获批上市,用于治疗白癜风;并已于新加坡、台湾市场递交注册申请。此外,康联达健康与君实生物合作的特瑞普利单抗(抗PD-1单抗)也于本年度内递交了马来西亚、菲律宾、印尼、泰国、越南市场的注册申请。CDMO业务方面,康哲药业联营公司PharmaGend位于新加坡大士的生产工厂已取得美国FDA的GMP认证,并顺利完成新加坡HSA现场审计,将为全球药企提供CDMO服务,同时也为康哲药业海外生产的供应链安全提供有力保障。站在新征程的起点,康哲药业以变应变、向新而行,坚定执行"创新驱动、效率优先、专科突破、全球布局"战略,重塑增长曲线,以更加多元、更有韧性的业务格局,迈向高质量发展的新阶段,将为患者提供更多优质治疗选择,为股东创造长期稳定回报。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广,非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息,请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请,不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制,但康哲药业并无进行任何说明或保证、明述或暗示,或其他表述,对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述,该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证,存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测,康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com.

20 3 月, 2025

南山铝业国际香港招股 增长强劲的东南亚氧化铝龙头

香港, 2025年3月19日 - (亚太商讯 via SeaPRwire.com) - 近期,港股IPO市场持续升温,各行业龙头纷纷赴港上市,吸引全球投资者的关注和参与。3月17日,东南亚氧化铝龙头南山铝业国际(2610.HK)启动港股招股。本次IPO,南山铝业国际计划募资规模(绿鞋前)为23.5-27.8亿港元。发售价介乎26.6-31.5港元之间,每手100股,预计于3月25日登陆香港联交所主板。据了解,南山铝业国际(Nanshan Aluminium International) 是位于印度尼西亚廖内群岛省民丹岛经济特区的氧化铝生产商,市场份额稳居东南亚氧化铝行业首位。此外,南山铝业国际的母公司是中国电解铝行业龙头之一。目前南山铝业国际的采购、生产、销售环节均在印度尼西亚本土、东南亚或其他国家实现,是中资背景企业在海外实现外循环完整布局的典范。成本优势显著 稳健经营底盘稳固南山铝业国际主要面对全球市场提供优质冶金级氧化铝粉,凭借印度尼西亚得天独厚的资源优势,公司铝土矿、煤炭、员工成本均远低于行业水平,搭配其自建的160兆瓦发电厂、3.5万吨级深水码头、煤制气厂和专用水库等配套设施,进一步降低了公司的生产成本,使其成为全球氧化铝厂商中单吨成本最低的公司,单吨氧化铝生产成本仅约1700元人民币,仅为当前中国企业平均生产成本的55%。此外,公司于印度尼西亚的主要营运附属公司BAI所在的印度尼西亚廖内群岛省民丹岛经济特区让其享有长达20年的所得税豁免政策,为公司构筑了远超同业的成本护城河。值得一提的是,作为成品铝的上游产品,国际氧化铝价格受全球三大供给地区澳大利亚、几内亚和印度尼西亚的出口政策,开采和加工成本、远洋运费和同行业企业开工率等多种因素扰动,而南山铝业国际强大的成本优势,让其能更为从容应对市场波动,助力公司业务稳健经营。财务表现优异 行业高景气下成长前景可期在量价齐升的行业周期驱动下,南山铝业国际业绩呈现爆发式增长。财务数据显示,2021-2024年,公司营收分别为1.7亿、4.7亿、6.8亿、10.2亿美元,年复合增长率高达80%;同期公司净利润分别为0.4亿、1.0亿、1.7亿、4.6亿美元,年复合增长率高达126%。与此同时,南山铝业国际盈利能力持续提升。2021-2024年,公司毛利率分别为25.9%、24.0%、29.2%、50.6%。在24年氧化铝周期上升信道期间,公司依托印度尼西亚资源禀赋构筑的「成本凹地」稳定优势,成功将产品价格上行红利转化为盈利增长,推动自身毛利率增长至超过50%。此外,在2023年氧化铝下行周期内,公司毛利率依然保持接近30%的水平,展现出了公司的盈利韧性,印证了公司的成本优势。从行业前景看,2023年,印度尼西亚为东南亚氧化铝产能最大的国家(占该地区产能的70%以上)。受限于中国国内氧化铝、电解铝生产的产能规模限制,东南亚的氧化铝产量增速将显著高于全球水平,2019年至2023年复合年增长率达到23.3%,显著高于全球1.8%的年复合增长率,后续预计将以7.1%的速度增至2028年的851.5万吨,市场前景十分广阔,为南山铝业国际提供发展机遇。目前,南山铝业国际氧化铝年产能达200万吨,且其三期、四期扩建项目正在推进之中,预计于2026年底总产能将提升至400万吨。未来,随着其产能全面投产,公司东南亚第一市场地位将得到持续夯实。股东战略合作加持,赢得国际产业投资人广泛认可除控股股东南山铝业外,南山铝业国际还拥有齐力铝业、Santony家族等强有力的战略合作伙伴作为股东。公司第二大股东为齐力铝业,其为东南亚最大的综合铝业公司,并已于马来西亚上市,齐力铝业已经与公司签订了10年期氧化铝承购安排,与公司建立了稳定、长期的下游合作关系;公司第三大股东为Santony家族,公司与其保持了良好的关系,确保本公司优质铝土矿、煤炭等原料的稳定供应。本次上市过程中,公司也吸引了嘉能可Glencore、厦门象屿的间接附属公司香港拓威、瑞中国际、Indika Energy等多家知名大宗商品、能源贸易领域基石投资人的加持,并有望为公司带来更多的资源赋能和合作机会。 Copyright 2025 亚太商讯 via SeaPRwire.com.

20 3 月, 2025

Kingsoft Announces 2024 Annual and Fourth Quarter Results

FINANCIAL HIGHLIGHTSRMB’000For the yearended 31 DecemberFor the 3 monthsended 31 December 2024 2023 20242023Revenue10,317,9048,533,6112,792,4782,310,135- Office software and services5,121,0754,556,5131,501,1811,285,691- Online games and others5,196,8293,977,0981,291,2971,024,444Gross Profit8,580,4767,030,3432,343,3441,896,250Operating Profit3,646,6232,226,8821,106,890714,794Profit Attributable to Owners of the Parent1,551,613483,457460,241205,435Basic Earnings Per share (RMB)1.160.360.350.15HONG KONG, Mar 19, 2025 - (ACN Newswire via SeaPRwire.com) - Kingsoft Corporation Limited (“Kingsoft” or the “Company”; HKEx stock code: 03888), a leading Chinese software and Internet service company, has announced its 2024 annual results and fourth quarter results for the period ended 31 December 2024.For the year of 2024, the revenue of Kingsoft increased 21% year-on-year to RMB10,317.9 million. Revenue from the office software and services, and online games and others represented 50% and 50% of the Group’s total revenue for the year of 2024, respectively. Gross profit increased 22% year-on-year to RMB8,580.5 million. In 2024, the Group’s operating profit reached 3,646.6 million, a strong year-on-year increase of 64%.For the fourth quarter of 2024, the Company’s revenue increased 21% year-on-year to RMB2,792.5 million. Revenue from the office software and services, and online games and others represented 54% and 46% of the Group’s total revenue for the fourth quarter of 2024, respectively. Gross profit for the fourth quarter of 2024 increased 24% year-on-year to RMB2,343.3 million. The Group’s gross profit margin increased by two percentage points year-on-year and kept flat quarter-on-quarter to 84%.Mr. Jun LEI, Chairman of the Company, commented: “Throughout 2024, we remained dedicated to technology empowerment, focused on strengthening our core capabilities, and achieved the milestone of surpassing 10 billion in revenue for the first time. Kingsoft Office Group focuses on the core strategic directions of ‘multiscreen, cloud, content, collaboration, AI’ and continues to increase investment in R&D in the fields of collaboration and AI. This drives product iteration and upgrades through innovation, creating a product system that better meets user needs, effectively enhancing its market competitiveness and industry influence in the intelligent office business. For the online games business, we deeply engage in classic wuxia IP, actively exploring new genres to provide users with diverse gaming experience.”Mr. Tao ZOU, Chief Executive Officer of the Company, added, “The Group’s overall performance in 2024 was strong, achieving record highs in revenue, profitability, and core operating metrics. In 2024, the total revenue reached RMB10,317.9 million, a year-on-year increase of 21%. Among them, revenue from office software and services business was RMB5,121.1 million, a year-on- year increase of 12%. Revenue from online games and others business was RMB5,196.8 million, a robust year-on-year increase of 31%. In 2024, the Group’s operating profit reached 3,646.6 million, a strong year-on-year increase of 64%, and the operating profit margin increased from 26% in 2023 to 35%.”BUSINESS REVIEW Office Software and ServicesIn 2024, revenue from the office software and services business increased 12% year-on-year to RMB5,121.1 million. The increase was primarily due to increased revenue from WPS individual and WPS 365 businesses. The increase of WPS individual business was mainly attributed to improved conversion rates, driven by the synergistic development of traditional and AI-powered features. As for the WPS 365 business, the revenue grew notably, since we continuously consolidated customer advantages in central state-owned enterprises, and accelerated penetration into private and local state-owned enterprises. Revenue from the office software and services business for the fourth quarter of 2024 increased 17% year-on-year to RMB1,501.2 million. The year-on-year increase was mainly attributable to WPS 365 and WPS individual businesses of Kingsoft Office Group. The increase of WPS 365 business was primarily due to the increased number of paying enterprises, supported by the enhanced AI and collaboration capabilities as well as the replication of typical industry solutions. The increase of WPS individual business was primarily driven by enriched the membership benefits including wide adoption of AI-powered features, which enhanced user experience and improved conversion rates.In 2024, Kingsoft Office Group remained committed to a user-centric approach, continuously enhancing product features and services driving dual growth in both user base and monetization capabilities. For WPS domestic individual business, we accelerated the iteration of WPS AI and launched the WPS AI Assistant, empowering users with intelligent office capabilities. AI-powered enhancements were also integrated into WPS Office major components, significantly lowering the barrier to AI adoption. By the end of 2024, the number of daily active devices of WPS PC in the domestic market exceeded 100 million.  In overseas market, we prioritized expansion in high-value regions, leveraged differentiated value-added features to attract users.For institutional customers, WPS 365 underwent a brand-new upgrade. It includes WPS Office, WPS Teams, and WPS AI Enterprise Edition, successfully integrating document management, collaboration, and AI capabilities to enable a one-stop AI-powered office solution. Additionally, we launched Kingsoft Government Office Model, and released WPS AI Government Edition, offering intelligent solutions for government.For WPS software business, we advanced software legalization and domestic adoption, empowering government and enterprises in digital transformation. In localization, we strengthened our presence in government and key industries like finance, energy, and telecommunications, assisting clients in building secure, self-sufficient digital offices.Online Games and othersIn 2024, revenue from the online games and others business for the year of 2024 increased 31% year-on-year to RMB5,196.8 million. The significant year-on-year increase was primarily attributed to the strong performance of JX3 Online and anime game Snowbreak: Containment Zone. Revenue from the online games and others business for the fourth quarter of 2024 increased 26% year-on-year to RMB1,291.3 million. The notable year-on-year increase was mainly attributable to the solid performance from JX3 Online, as the launch of JX3 Ultimate  in 2024 further boosted players’ engagement, and the revenue contribution from the anime game Snowbreak: Containment Zone, driven by the continuous content updates.In 2024, the online games business has achieved outstanding growth, with a record number of new users. JX3 Online achieved integration across platforms, further boosting players' enthusiasm. The vitality of the JX3 Online IP continued to flourish, with its cultural ecosystem recovered, and has attracted a number of young players. World of Sword Origin, as a classic wuxia inheritance work, continued to operate stably and was deeply loved by players. Meanwhile, progress was also made in anime shooter game, Snowbreak: Containment Zone initially broke into new game genre through product positioning, continuous iteration, and user interaction.Moving into 2025, we are set to introduce several new titles while continuing to refine our flagship game, JX3 Online. The sci-fi mech game Mecha BREAK, targeting the global market, is set to launch in the first half of the year. This title aims to break into the sci-fi mech genre and establish a new original IP, further enriching our game portfolio. And the Fate of Sword: Zero, the new mobile game from the classic Sword series, will be also released. The in-house developed shooter game Wild Assault, built with Unreal Engine 5, is expected to launch on platforms, including Steam and Epic Games Store in April.Mr. Jun LEI concluded, “Looking ahead to 2025, we will continue to iterate on our core products and technologies to meet user needs and promote high-quality business development. Kingsoft Office Group will deepen AI adoption in office productivity, strengthen WPS 365’s capabilities, and expand global market reach. Targeting the global market, online games business will continue focusing on prime games, expand into new genres, and strive to create high-quality games that are deeply loved by players. We will adhere to technology empowerment, focus on product and service innovation, and create long-term value for our shareholders.”About Kingsoft Corporation LimitedKingsoft (3888.HK) is a leading Chinese software and internet service company listed on the Hong Kong Stock Exchange. It has three main subsidiaries: Kingsoft Office, Seasun Holdings and Kingsoft Shiyou. With the implementation of the “transformation toward mobile internet” strategy, Kingsoft has completed a comprehensive transformation in its overall business and management model. The Company has established a strategic layout with office software and interactive entertainment as its pillars, and cloud services and artificial intelligence as its new starting points. Kingsoft has over 8,000 employees worldwide and holds a significant market share domestically. For more details, please refer to http://www.kingsoft.com.Kingsoft Investor Relations:Li YinanTel: (86) 10 6292 7777Email: ir@kingsoft.comFor further queries, please contact Hill and Knowlton:Ovina Zhu  Tel: (852) 5933 9083Email: kingsofthk@hkstrategies.com Copyright 2025 JCN Newswire via SeaPRwire.com.

20 3 月, 2025

TRENDE Secures JPY 1.07 Billion Investment to Expand Renewable Energy Initiatives and Strategic Partnerships

TOKYO, Mar 19, 2025 - (JCN Newswire via SeaPRwire.com) - TRENDE Inc., a leading renewable energy solutions provider in Japan, today announced the successful completion of a JPY 1.07 billion (approximately USD 7.2 million) funding round through third-party allocation. The investment round welcomes four strategic partners as new shareholders: Tokyo Century Corporation, National Federation of Agricultural Cooperative Associations (ZEN-NOH), Zen-Noh Energy Corporation, and Toshiba Infrastructure Systems & Solutions Corporation.This capital infusion will accelerate TRENDE's growth initiatives, including the expansion of its flagship solar and battery leasing service “Teraris,” and further development of its innovative peer-to-peer (P2P) energy trading platform.Masashi Nishio, CEO of TRENDE Inc., commented: “We are thrilled to welcome these esteemed companies as strategic investors and partners. Their expertise and resources will significantly enhance our ability to deliver innovative renewable energy solutions at scale. Together, we aim to accelerate Japan's transition toward a decentralized, low-carbon future.”Strategic Collaboration Highlights:Tokyo Century Corporation: TRENDE will collaborate closely with Tokyo Century in finance and asset management to scale its renewable energy leasing services, enabling more residential customers to adopt solar power and battery storage systems with zero upfront costs.ZEN-NOH & Zen-Noh Energy Corporation: As part of ZEN-NOH's Smart Agri Community Project, TRENDE is partnering with Zen-Noh Energy through its retail electricity brand “JA Denki” to pilot P2P electricity trading in Gunma Prefecture. Leveraging blockchain technology, this initiative promotes local production and consumption of renewable energy within agricultural communities. Plans are underway to expand this model nationwide, providing sustainable energy solutions specifically tailored for farmers and rural communities.Toshiba Infrastructure Systems & Solutions Corporation: TRENDE has collaborated with Toshiba on the “Digital Implementation Acceleration Project” in Ehime Prefecture, integrating Toshiba's advanced Vehicle-to-Everything (V2X) technology with TRENDE's P2P electricity trading platform. This partnership aims to demonstrate effective local renewable energy utilization strategies, contributing towards regional decarbonization goals. Moving forward, both companies will jointly promote this innovative model across municipalities throughout Japan.About TRENDE Inc.TRENDE Inc. provides customer-centric renewable energy solutions in Japan through its solar and battery leasing service “Teraris” (https://teraris.jp/) and innovative peer-to-peer (P2P) electricity trading platform. With a mission to accelerate renewable energy adoption and redefine Japan's energy ecosystem, TRENDE is backed by prominent investors including Itochu Corporation, Idemitsu Kosan Co., Ltd., and Dubai Electricity and Water Authority (DEWA). For more information, visit https://trende.jp/.Investor Information    Company Name, Headquarters, Representative, Established, WebsiteTokyo Century Corporation, Tokyo, Koichi Baba, July 1, 1969, www.tokyocentury.co.jp National Federation of Agricultural Cooperative Associations (ZEN-NOH)      Tokyo, Yoshifumi Kuwata, March 30, 1972, https://www.zennoh.or.jp Zen-Noh Energy Corporation, Tokyo, Masayuki Wada, Dec 7, 1979, https://zennoh-energy.co.jp/Toshiba Infrastructure Systems & Solutions Corporation, Kawasaki, Taro Shimada       July 1, 2017, https://www.global.toshiba/jp/company/infrastructure.html  Media Contact:TRENDE Inc.Public RelationsEmail: pr@trende.jp Copyright 2025 JCN Newswire via SeaPRwire.com.

20 3 月, 2025

Fujitsu and FICO partner to accelerate digital transformation in financial services

Kawasaki, Japan and Bozeman, Mont., Mar 19, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and FICO, a global analytics software leader, today announced they have entered into a partnership to expand FICO’s solutions to Japan, with plans to extend into other financial markets. Under the partnership, Fujitsu will provide FICO® platform’s Omni-Channel Engagement Capabilities to Japanese financial institutions from July 2025, while also broadening the solution lineup and exploring opportunities for further regional expansion to support the financial industry’s digital transformation.FICO’s technologies, including predictive analytics, fraud prevention and decision management, offer high-levels of accuracy, reliability and predictive power and are utilized by hundreds of leading companies around the world. By leveraging Fujitsu's knowledge of the financial sector, technological capabilities, and customer base to accelerate the expansion of FICO’s services in Japan, the two companies will enable financial institutions to provide enhanced support to users and ensure the stability of the financial system.Through this partnership, Fujitsu will support FICO services from consulting to full system implementation, with FICO providing technical expertise. The expansion of FICO’s services in Japan is expected to meet the increasing need for flexibility amid an aging population and evolving workstyles.Masaru Yagi, Corporate Executive Officer, EVP, Fujitsu Limited comments:“This partnership between Fujitsu and FICO is a critical step in broadening digital transformation support for financial institutions. By combining Fujitsu’s technological know-how with FICO’s highly rated range of data analytics solutions, we will offer a new level of advanced services to the financial instituions of Japan. In the future we will broaden the range of solutions and expand to other regions so that we can provide robust support for digital transformation in the financial sector.”Alexandre Graff, Vice President, Global Partners & Alliances, FICO comments:“Fujitsu’s deep industry expertise, trusted customer relationships and robust integration capabilities, combined with FICO’s advanced decisioning and analytics, create a powerful force for innovation in financial services. We’re excited about the opportunities this collaboration unlocks — enabling banks, card issuers and other FSIs in Japan to modernize customer engagement, enhance risk management, and accelerate growth. Together, we are delivering a future of smarter, more connected banking and payments.”More information: https://www.fico.com/en/fico-platformAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About FICOFICO (NYSE: FICO) powers decisions that help people and businesses around the world prosper. Founded in 1956, the company is a pioneer in the use of predictive analytics and data science to improve operational decisions. FICO holds more than 200 US and foreign patents on technologies that increase profitability, customer satisfaction and growth for businesses in financial services, insurance, telecommunications, health care, retail and many other industries. Using FICO solutions, businesses in more than 80 countries do everything from protecting 4 billion payment cards from fraud, to improving financial inclusion, to increasing supply chain resiliency. The FICO® Score, used by 90% of top US lenders, is the standard measure of consumer credit risk in the US and has been made available in over 40 other countries, improving risk management, credit access and transparency.Learn more at https://www.fico.comJoin the conversation at https://x.com/FICO_corp &https://www.fico.com/blogs/For FICO news and media resources, visit https://www.fico.com/newsroomFICO and Falcon are registered trademarks of Fair Isaac Corporation in the U.S. and other countries.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesFICORICE Communications for FICOE-mail: fico@ricecomms.comSaxon ShirleyFICO+65 9171 0965saxonshirley@fico.com Copyright 2025 JCN Newswire via SeaPRwire.com.

19 3 月, 2025

Dr. Li Chen Honored as A Leading Figure in Shanghai’s Industry and Commerce

SHANGHAI, Mar 18, 2025 - (ACN Newswire via SeaPRwire.com) - On March 17th, the highly anticipated 7th Commendation and Exchange Conference for the Leading Figures in Shanghai's Industry and Commerce was brought to a successful conclusion. Dr. Li Chen, the founder and CEO of Hua Medicine, was awarded the title of "A Leading Figure in Shanghai's Industry and Commerce" for his outstanding contributions and innovative leadership in the field of biomedicine. He also gave a speech representing the leading figures at the ceremony. (Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce)The initiative to select the leading figures in Shanghai's industry and commerce dates back to 2006. It is jointly sponsored by the Shanghai Federation of Industrial Economics and the Shanghai Federation of Economic Organizations, and jointly organized by the Shanghai General Chamber of Commerce and the Shanghai Enterprise Confederation. The selection aims to encourage industrial and commercial leaders and entrepreneurs to work hard, and make new contributions to Shanghai's cultivation and development of new quality productivity, and the acceleration of the construction of the "Five Centers" and the modern industrial system. A total of 67 entrepreneurs from various industries were selected. With more than 30 years of experience in new drug R&D and management, Dr. Li Chen returned to Shanghai from the U.S. in 2004, and participated in the establishment of Roche China R&D Center, the first R&D center of a multinational company in Shanghai, bringing the advanced experience, talent concept, technical standards and quality management system of international new drug R&D to China, and contributing to the establishment of the environment of China's biopharmaceutical industry. Since founding Hua Medicine in 2010, he has been committed to the research and development of new drugs in the field of diabetes. He has continuously overcome the technical difficulties, filled the domestic gaps, transformed technological advantages into industrial advantages and development momentum, led the company to seize the commanding heights of the future development in diabetes treatment, and achieved significant breakthroughs in the field of Glucokinase Activators (GKA).Under the leadership of Dr. Li Chen, by applying the concept of blood glucose homeostasis treatment, dorzagliatin (trade name: HuaTangNing), a globally first-in-class, China-first-launch, Class 1 new drug of GKA independently developed by Hua Medicine, was successfully approved for marketing by the National Medical Products Administration (NMPA) in September 2022. This achievement not only introduced a revolutionary treatment modality for diabetes but also plugged a long-standing gap in global GKA research and development. The entire R&D odyssey and the successful market entry of dorzagliatin are a testament not only to Dr. Li Chen's intrepid innovative spirit and unyielding pursuit in scientific exploration but also to the vanguard role played by Chinese innovative drug enterprise managers. (Dr. Li Chen gave a speech representing the leading figures at the ceremony)On the path of innovative R&D, by practicing the model of joint innovation and working closely with enterprises in the industrial chain to share resources, Dr. Li Chen, together with numerous pioneers in innovative drugs, has jointly promoted the prosperous development of the biomedicine industry ecosystem.Looking to the future, Dr. Li Chen will continue to lead Hua Medicine to move forward on the path of innovation and constantly explore new directions in the field of diabetes treatment. Hua Medicine is actively promoting the development of the second-generation GKA and the fixed combination formulation of dorzagliatin, with the aim of making progress in the fields of personalized diabetes treatment and diabetes complications. The company will also continue to expand the R&D of innovative drugs in the field of metabolic diseases. By utilizing the existing technological accumulation and R&D experience, combine big data and artificial intelligence technology, it will explore more treatment spaces in terms of immune homeostasis and neural homeostasis, bringing more good and new drugs to patients in China and even around the world.Hua Medicine will also continue to expand the research and development of innovative drugs in the field of metabolic diseases. By leveraging its existing technological accumulation and R&D experience, it will explore more therapeutic possibilities in the aspects of immune homeostasis and neural homeostasis, bringing more excellent and new drugs to patients in China and even around the world. It will make new contributions to promoting scientific and technological innovation, fostering new and high-quality productive forces, and building a modern industrial system.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing(dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2025 JCN Newswire via SeaPRwire.com.

19 3 月, 2025

数字生态矩阵趋完善:通通AI社交集团公告并购两企

香港, 2025年3月18日 - (亚太商讯 via SeaPRwire.com) - 通通AI社交集团有限公司(股票代码:00628.HK,以下简称"通通AI社交集团"或"集团")发布收购公告:集团通过合同安排完成收购两家运营公司-北京爆款连连文化科技有限公司(以下简称"爆款连连")、共域通兑(海南)科技有限公司(以下简称"共域通兑"),由通通AI社交集团享受全部经济利益,并获全面豁免关联交易。其中,通通AI社交集团此前已经持有共域通兑50%股份,本次收购余下50%股份,实现对共域通兑100%控股。完成上述两家公司收购后,通通AI社交集团将进一步丰富数字内容生态服务能力,以及深化集团商业生态协同,持续拓展和完善 "社交+商业"领域的战略布局,充分把握互联网WEB3.0时代和数字经济发展机遇。"爆款连连"深耕内容生产 助力商业化引流根据公告,本次收购的爆款连连,立足于新媒体影视网络生态内容领域,业务涵盖影视制作、网生内容开发、影视宣传发行以及艺人培训等多个板块,实现了影视产业链的一体化运营。目前,该公司主要聚焦于网剧和微短剧等新媒体平台赛道,为年轻受众打造高品质、精品化的影视创新内容,全力构建网生环境下的青春影视制作产业链。此次收购爆款连连,意味着通通AI社交集团将会拥有可持续的网络内容生产能力-短视频、短剧等,在自家平台集中生产与传播,符合当前微短剧高热度的发展趋势,持续吸引更多用户,提高用户在平台的停留时间,助力用户引流和商业转换。"共域通兑"打通会员运营壁垒 激活生态活力公开信息显示,本次收购的共域通兑主要通过建立商家积分互通互兑的机制,开展跨客户资产互通的业务,实现跨商户会员积分的兑换和会员共享,以此推动品牌商家对中小商家的品质权益赋能,以及中小商家对品牌商家的流量赋能。共域通兑旨在助力发展高质量会员经济共域,不同领域、不同行业、不同群体之间相互开放通兑,助力商家资产实现价值提升和低成本裂变获客。完成收购后,通通AI社交集团将获得通用兑换业务核心能力及互联网系统,助力自身实现不同业务间会员体系共享,打破各业务运营阻碍。届时,集团在互联网领域的引流能力将显著提升,各业务间的协同发展也将获得巨大驱动力。棋落两子巩固"社交+商业"战略布局至此,通通AI社交集团的"社交+商业"战略布局再落两子,其所打造的综合互联网数字生态矩阵更趋完善。当下,数字经济浪潮澎湃,AI+智能技术方兴未艾,数字化转型与创新已成为企业前行的核心引擎。通通AI社交集团董事会认为,此次对爆款连连和共域通兑的收购举措,将促使集团顺利切入全新的业务领域,继续巩固“社交+商业”战略布局。这不仅会为集团开拓多元的商业契机,提高其综合竞争力与风险抵御能力,长远来看,更将为集团股东创造更为可观的价值回报。当前,元宇宙、人工智能等技术正值风口,持续为Web3.0 时代的数字经济注入创新动能,驱动互联网新平台、新技术、新业态加速变革。对此,业内分析认为,在此瞬息万变的商业环境中,通通AI社交集团的此番收购动作颇具战略眼光,彰显企业在前沿技术布局和商业生态构建层面的超前洞察力。据悉,此次收购获得董事会一致审议通过后,通通AI社交集团将进一步扩大业务版图,促进"社交+商业"生态版图下的资源整合,并有望开拓更广阔的发展空间。 Copyright 2025 亚太商讯 via SeaPRwire.com.

19 3 月, 2025

氧化铝东南亚龙头南山铝业国际开启香港招股

香港, 2025年3月18日 - (亚太商讯 via SeaPRwire.com) - 南山铝业国际(Nanshan Aluminium International) 是位于廖丙群岛省民丹岛经济特区的氧化铝生产商,其子公司享受印尼园区20年所得税免税政策。市场份额稳居东南亚氧化铝行业首位,得益于印尼当地丰富的铝土矿供应、廉价的能源供应,以及员工成本优势等,南山铝业国际的单体盈利能力远高于高于同行业可比公司。南山铝业国际的母公司是中国电解铝行业龙头之一。根据印尼政府的政策,从2023年6月开始禁止铝土矿出口,并推动在本国加工铝土矿的发展。该政策客观上催生了南山铝业国际在印尼加工的业务布局。2019年开始,南山铝业国际200万吨氧化铝项目正式开工建设,2021年5月建成投产,当年即实现2.8亿元人民币净利润。目前南山铝业国际的采购、生产、销售环节均在印尼本土、东南亚或其他国家实现,是中资背景企业在海外实现外循环完整布局的典范。南山铝业国际已于2025年3月17日启动港股IPO簿记,现正招股中,公司发行估值区间160-190亿港元,发行比例为15%,计划募资规模为27.0-32.0亿港元。预计2025年3月25日于香港联交所主板挂牌上市。单吨生产成本全球最低,盈利空间高,经营稳健南山铝业国际主要面对全球市场提供优质冶金级氧化铝粉,公司目前氧化铝年产能达200万吨,随着未来三期、四期扩建项目的推进,总产能将于2026年底提升至400万吨。公司自建设以来均依靠股东自有资金,目前有息负债为零,净资产接近100亿港币。凭借印尼得天独厚的资源优势,南山铝业国际铝土矿、煤炭、员工成本均远低于行业水平,搭配自建的160兆瓦发电厂、3.5万吨级深水码头、煤制气厂和专用水库等配套设施,公司是全球氧化铝厂商中单吨成本最低的公司,单吨氧化铝生产成本仅约1700元人民币,仅为当前中国企业平均生产成本的55%。此外,公司的子公司所在的印尼经济特区更赋予其长达20年的所得税豁免政策,为公司构筑了远超同业的成本护城河。面对国际氧化铝价格的波动,南山铝业国际更凸显成本优势的稳健经营的优势。铝作为全球最重要的大宗商品之一,在汽车、3C产品、饮料罐、食品包装等领域均有大量的应用,因此国际需求稳步上升。作为成品铝的上游产品,国际氧化铝价格扰动因素较多,包括全球三大供给地区澳大利亚、几内亚和印度尼西亚的出口政策,开采和加工成本、远洋运费和同行业企业开工率等等。长期看,氧化铝的供应和需求将保持动态平衡。财务表现优异财务数据显示,在量价齐升的行业周期驱动下,公司业绩呈现爆发式增长:营业收入、净利持续飙升:2021-2024年公司营收分别为1.7亿、4.7亿、6.8亿、10.2亿美元,年复合增长率高达80%;2021-2024年公司净利润分别为0.4亿、1.0亿、1.7亿、4.6亿美元,年复合增长率高达126%;穿越周期的盈利韧性:2021-2024年公司毛利率分别为25.9%、24.0%、29.2%、50.6%。公司依托印尼资源禀赋构筑的「成本凹地」稳定优势,在24年氧化铝周期上升通道期间,成功将产品价格上行红利转化为自身毛利率增长超逾50%。此外,公司的盈利质量也得到了充分的逆周期验证,2023年氧化铝下行周期内,公司也展现出了独特的抗周期特质,毛利率水平依然可以保持接近30%水平,足以印证公司的成本护城河深度。增长前景广阔2023年,印尼为东南亚氧化铝产能最大的国家(占该地区产能的70%以上),在全球氧化铝设计产能分布中位居第五,仅次于中国、澳大利亚、巴西及印度。更重要的是,受限于中国国内氧化铝、电解铝生产的产能规模限制,东南亚的氧化铝产量增速将显著高于全球水平,从2019年的23.7亿吨增至2023年的54.8亿吨,复合年增长率达到23.3%,显著高于全球1.8%的年复合增长率,后续预计将以7.1%的速度增至2028年的85.1亿吨,氧化铝行业市场前景十分广阔。未来,伴随公司400万吨产能全面投产,南山铝业国际的东南亚第一市场地位可以得到进一步巩固,叠加可预期的氧化铝产能翻倍的盈利贡献和广阔的市场前景需求,南山铝业国际作为优质投资标的属性将会进一步凸显。 Copyright 2025 亚太商讯 via SeaPRwire.com.

19 3 月, 2025

中国利郎公布二零二四年全年业绩

香港, 2025年3月18日 - (亚太商讯 via SeaPRwire.com) - 中国利郎有限公司(「中国利郎」或「本公司」,及其附属公司,统称「集团」;股份编号:1234)今天公布其二零二四年全年业绩。中国利郎主席兼非执行董事王冬星先生说:「二零二四年,全球局势依旧复杂多变,地缘政治及经济环境前景仍然复杂,国际贸易和关税等因素对实际经济的影响难以预测。作为行业的领先者,集团于年内坚定推进战略转型,善用科技加强企业管理,并在维持与分销商及各个合作伙伴合作并巩固全国销售网络的基础上,进一步优化渠道布局,提升运营效率,以实现更高质量的健康增长。」年内,集团收入同比增长3.0%至人民币36.5亿元。其中,轻商务系列增长27.2%,主要得益于单店平均销售额的强劲提升以及新零售管道的显著成效,延续二零二三年的良好势头。主系列销售下跌3.0%,主要由于集团于年内收回东北三省和江苏四省的分销商的分销权,转以直面消费者(DTC)模式经营,导致分销业务销售出现下降。此外,集团需向四个省份原分销商支付补偿金,并直接从销售收入扣减。毛利率为47.7%,同比轻微下降0.5个百分点,主要因为向分销商支付一次性补偿金,以及存货拨备回拨减少所致。股东应占利润为人民币4.6亿元(二零二三年: 人民币5.3亿元)。股东应占利润率为12.6%(二零二三年: 15.0%)。每股盈利为人民币38.51分。集团于年内保持财政稳健,现金流充足。董事会建议派发末期股息每股9港仙及特别末期股息每股3港仙,连同已派发的中期股息,全年每股派息合共30港仙,维持稳定的派息比率。集团积极响应新零售强劲的发展趋势,采取全新战略,将电商平台从清理库存的渠道改革成为主攻新品的零售渠道。集团同时继续强化新零售的全平台布局,在原本的电商渠道布局的基础上开拓了「拼多多」及「得物」等多元在线渠道。新零售销售年内同比增长24%。面对不断变化的市场趋势,集团采取灵活的策略,坚实拥抱变革,通过多元的销售渠道和精准的市场定位使集团的产品和服务能够更切合中国男装消费者的购买习惯,从而促进销售提升。年内,集团年内布局渠道转型,在东北地区及江苏省率先推行「LILANZ主系列」的DTC模式,取代过去由一级分销商经营的模式。该等举措推动不足一年,已经让集团在东北地区及江苏省的实现显著增长,并预期为集团长远提供更大的贡献。此外,轻商务则继续采用直营模式及直营的电商销售模式。截至二零二四年十二月底,集团主系列店铺共2,451家,轻商务门店共322家,合计共2,773家,同比净增加78家。品牌推广方面,不断积极探索多元营销新方式,以「创新、质量、年轻化」为关键词,通过品牌战略升级、明星、数字化营销及社会责任践行等多维度举措,透过主系列和轻商务系列的产品持续革新,成功触达各线城市及不同年龄段的消费群体。集团去年提出「多品牌、国际化」发展策略已迈入实质阶段,并成功与国际公司合作,丰富自有产品组合。集团在去年八月通过控股合资形式,获得了高端高尔夫服饰品牌「MUNSINGWEAR」在中国地区的品牌所有权,相关库存接管已顺利进行。此外,集团筹备在马来西亚组开设海外门店进展顺利。二零二五年,中国利郎作将继续发挥自身优势,推动变革转型,把握市场整合的机会。集团目标在二零二五年净增加100家店铺,将优先选择在省会及地级市的优质购物商场开设新店,选址在高流量和高消费潜力的地区;同时增加在奥特莱斯商场的开店规模,以更相宜的价吸引消费者,并有效清理库存。集团亦会灵活关闭低效店铺,并严格控制成本开支,旨在提升店效的同时,确保资源对准投放于目标消费群。此外,为延续新零售业务的良好势头及把握市场机遇,集团今年将增加在在线销售新产品,目标新货品销售占电商销售总金额的比重能提高至80%。集团力求新零售业务于二零二五年实现15%或以上的增长,整体销售额达到不少于10%的增长。集团将按计划推进「多品牌、国际化」发展策略,集团旗下合资公司「MUNSINGWEAR」的在线销售预期在今年上半年正式启动,并于下半年开设首家实体门店。此外,集团预计上半年于马来西亚组开设首家门店,目前进展顺利。藉此,集团布局于二零二五年年底实现以「利郎LILANZ」、「利郎LESS IS MORE」和「MUNSINGWEAR」三个品牌,并在中国和马来西亚两个市场经营的目标,意味着在中国家传户晓的利郎品牌正式踏足国际。王冬星先生总结说:「面对未来的挑战与机遇,中国利郎将保持审慎乐观的态度。在坚定推行既定战略,持续推动新零售业务增长的同时,配合多品牌、国际化策略,扩大市场份额,提升品牌竞争力。集团致力实现更高质量的健康增长,从而巩固自身在男装行业的领导地位,为消费者提供更优质的产品与服务,并为股东创造更大的价值。」关于中国利郎中国利郎是中国领先的男装企业之一。作为一家综合时装企业,集团设计、采购、生产并以品牌「利郎LILANZ」及「利郎LESS IS MORE」销售优质男士商务及休闲服装。其产品于遍布中国31个省、自治区及直辖市的广阔零售及分销网络销售。 Copyright 2025 亚太商讯 via SeaPRwire.com.

19 3 月, 2025